MAB3326
Anti-Collagen Type IV Antibody, 7S Domain, clone IV-4H12
clone IV-4H12, Chemicon®, from mouse
Sinónimos:
Anti-BSVD, Anti-COL4A1s, Anti-PADMAL, Anti-RATOR
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Seleccione un Tamaño
100 μG
383,00 €
383,00 €
Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Solicitar un pedido a granel
Seleccione un Tamaño
Cambiar Vistas
100 μG
383,00 €
About This Item
Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
383,00 €
Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Solicitar un pedido a granel
Productos recomendados
origen biológico
mouse
Nivel de calidad
forma del anticuerpo
purified antibody
tipo de anticuerpo
primary antibodies
clon
IV-4H12, monoclonal
reactividad de especies
human
no debe reaccionar con
rat
fabricante / nombre comercial
Chemicon®
técnicas
ELISA: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable
isotipo
IgG1κ
Nº de acceso NCBI
Nº de acceso UniProt
Condiciones de envío
dry ice
modificación del objetivo postraduccional
unmodified
Información sobre el gen
human ... COL4A1(1282)
Especificidad
Specifically reactive with human Type IV Collagen.
Inmunógeno
Epitope: 7S Domain
Aplicación
Research Category
Cell Structure
Cell Structure
Research Sub Category
ECM Proteins
ECM Proteins
This Anti-Collagen Type IV Antibody, 7S Domain, clone IV-4H12 is validated for use in ELISA, WB, IH(P) for the detection of Collagen Type IV.
Western blot. Detects human type IV collagen from human placental tissues at 2 μg/mL, giving a band at approximately 92 kDa. Optimal working dilutions must be determined by end user.
Forma física
Format: Purified
Liquid in 0.1 M sodium phosphate buffer, pH 7.0, containing 2% protease-free bovine serum albumin.
Almacenamiento y estabilidad
Maintain frozen at -20°C in undiluted aliquots for up to 12 months.
Nota de análisis
Control
POSITIVE CONTROL: human placental tissues.
POSITIVE CONTROL: human placental tissues.
Otras notas
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Información legal
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Cláusula de descargo de responsabilidad
Manufactured by Daiichi Fine Chemical Co., Ltd
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Código de clase de almacenamiento
12 - Non Combustible Liquids
Clase de riesgo para el agua (WGK)
WGK 2
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Rashmi Ramakrishnan et al.
ACS biomaterials science & engineering, 6(5), 2740-2756 (2021-01-20)
Regeneration of large-sized acute and chronic wounds provoked by severe burns and diabetes is a major concern worldwide. The availability of immunocompatible matrix with a wide range of regenerative medical applications, more specifically, for nonhealing chronic wounds is an unmet
Tiina A Jokela et al.
Frontiers in cell and developmental biology, 6, 41-41 (2018-05-03)
The existence of rare cancer cells that sporadically acquire drug-tolerance through epigenetic mechanisms is proposed as one mechanism that drives cancer therapy failure. Here we provide evidence that specific microenvironments impose non-sporadic expression of proteins related to epithelial plasticity and
Yuliya Nashchekina et al.
Polymers, 14(21) (2022-11-12)
The lack of suitable functional groups for cell adhesion on the surface of Polycaprolactone (PCL) is one of the main limitations in order to use PCL for biomedical applications. The aim of this research is to modify the PCL film
Matthew Nolan et al.
Acta neuropathologica communications, 8(1), 98-98 (2020-07-04)
Degeneration of the primary motor cortex is a defining feature of amyotrophic lateral sclerosis (ALS), which is associated with the accumulation of microscopic protein aggregates in neurons and glia. However, little is known about the quantitative burden and pattern of
Filtros activos
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
